Phase II study of neo-adjuvant chemotherapy with combination therapy of gemcitabine and S-1 in patients with resectable pancreatic cancer
Phase 2
Recruiting
- Conditions
- resectable pancreatic cancer
- Registration Number
- JPRN-UMIN000005912
- Lead Sponsor
- Tokai university, school of medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
1)pulmonary fibrosis or interstitional pneumonaitis 2)prior anti-cancer therapy(chemotherapy,radiation therapy ,chemoradiation therapy) 3)active infection 4)syncronous cancers 5)severe complication 6)severe mental disorder 7)watery diarrhea 8)pregnancy 9)iodine allergy
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method R0 resection rate
- Secondary Outcome Measures
Name Time Method resection rate, adverse effect, completion rate, recurrence free survival, two-year survival rate, pathological effect